全文获取类型
收费全文 | 2270篇 |
免费 | 134篇 |
国内免费 | 13篇 |
专业分类
耳鼻咽喉 | 48篇 |
儿科学 | 165篇 |
妇产科学 | 72篇 |
基础医学 | 305篇 |
口腔科学 | 29篇 |
临床医学 | 139篇 |
内科学 | 551篇 |
皮肤病学 | 340篇 |
神经病学 | 92篇 |
特种医学 | 12篇 |
外科学 | 121篇 |
综合类 | 64篇 |
预防医学 | 38篇 |
眼科学 | 113篇 |
药学 | 295篇 |
中国医学 | 6篇 |
肿瘤学 | 27篇 |
出版年
2024年 | 3篇 |
2023年 | 36篇 |
2022年 | 43篇 |
2021年 | 60篇 |
2020年 | 99篇 |
2019年 | 92篇 |
2018年 | 90篇 |
2017年 | 87篇 |
2016年 | 64篇 |
2015年 | 68篇 |
2014年 | 110篇 |
2013年 | 291篇 |
2012年 | 70篇 |
2011年 | 88篇 |
2010年 | 62篇 |
2009年 | 76篇 |
2008年 | 85篇 |
2007年 | 88篇 |
2006年 | 89篇 |
2005年 | 69篇 |
2004年 | 48篇 |
2003年 | 72篇 |
2002年 | 70篇 |
2001年 | 59篇 |
2000年 | 50篇 |
1999年 | 55篇 |
1998年 | 38篇 |
1997年 | 41篇 |
1996年 | 39篇 |
1995年 | 28篇 |
1994年 | 24篇 |
1993年 | 24篇 |
1992年 | 25篇 |
1991年 | 21篇 |
1990年 | 23篇 |
1989年 | 10篇 |
1988年 | 18篇 |
1987年 | 12篇 |
1986年 | 9篇 |
1985年 | 10篇 |
1984年 | 12篇 |
1983年 | 6篇 |
1982年 | 6篇 |
1981年 | 13篇 |
1980年 | 8篇 |
1979年 | 3篇 |
1978年 | 6篇 |
1977年 | 3篇 |
1976年 | 6篇 |
1968年 | 2篇 |
排序方式: 共有2417条查询结果,搜索用时 15 毫秒
41.
《Expert opinion on pharmacotherapy》2013,14(10):1537-1548
Background: The lifelong prevalence of rotatory vertigo is 30%. Despite this high figure, patients with vertigo generally receive either inappropriate or inadequate treatment. However, the majority of vestibular disorders have a benign cause, take a favorable natural course, and respond positively to therapy. Objective: This review puts special emphasis on the medical rather than the physical, operative, or psychotherapeutic treatments available. Methods: A selected review of recent reports and studies on the medical treatment of peripheral and central vestibular disorders. Results/conclusions: In vestibular neuritis, recovery of the peripheral vestibular function can be improved by oral corticosteroids; in Menière's disease, there is first evidence that high-dose, long-term administration of betahistine reduces attack frequency; carbamazepine or oxcarbamazepine is the treatment of first choice in vestibular paroxysmia, a disorder mainly caused by neurovascular cross-compression; the potassium channel blocker aminopyridine provides a new therapeutic principle for treatment of downbeat nystagmus, upbeat nystagmus, and episodic ataxia type 2. 相似文献
42.
43.
44.
Stephen Brunton Harold S. Nelson David I. Bernstein Simon Lawton Susan Lu 《Postgraduate medicine》2017,129(6):581-589
Allergic rhinitis (AR) with or without conjunctivitis (AR/C) is associated with a significant health and economic burden, and is often accompanied by asthma. Pharmacotherapies are the mainstay treatment options for AR and asthma, but guidelines also recommend allergy immunotherapy (AIT). Unlike pharmacotherapies, AIT has the ability to modify the underlying immunologic mechanisms of AR and asthma with the potential for long-term benefits after treatment is discontinued. Immunotherapy may also prevent progression of AR/C to asthma. Sublingual immunotherapy (SLIT)-tablets are a self-administered alternative to subcutaneous immunotherapy that provide the benefits of AIT without the cost and inconvenience of frequent office visits or the discomfort of injections. SLIT-tablets are also an option that can be utilized by primary care clinicians. Pharmacotherapies are generally effective in mild disease although a number of patients remain uncontrolled. SLIT-tablets have proven efficacy for AR in adults, children, and poly-sensitized allergic patients. Indirect comparisons indicate that SLIT-tablets have superior or comparable efficacy compared with traditional pharmacotherapies for seasonal AR, and superior efficacy for perennial AR. House dust mite (HDM) SLIT-tablets have also demonstrated clinically relevant benefits for asthma, with significant observed reductions in daily inhaled corticosteroid use, risk of asthma exacerbations, and asthma symptoms. SLIT-tablets are well tolerated, with minimal risk of systemic allergic reactions. The most common treatment-related adverse events are oral site reactions such as oral pruritus and throat irritation. Based on the favorable efficacy and safety profile, as well as the convenience of at-home oral administration and disease-modifying effects, SLIT-tablets should be considered as an alternative or add-on treatment to pharmacotherapy for AR/C, and as an add-on treatment for HDM allergic asthma. 相似文献
45.
46.
47.
《Expert Review of Clinical Immunology》2013,9(2):143-155
Allergic rhinitis (AR) affects an estimated 20–40 million Americans annually. It is a multifaceted condition comprising a range of symptoms, including nasal congestion, arguably the most bothersome symptom. Of the various types of medications available for the treatment of AR, intranasal corticosteroids are considered the most effective. Mometasone furoate nasal spray is an intranasal corticosteroid with anti-inflammatory properties. It is indicated for the treatment of the nasal symptoms of seasonal AR and perennial AR in adults and children, for the prophylaxis of nasal symptoms of seasonal AR and for the treatment of nasal polyps. Numerous clinical trials have demonstrated that mometasone furoate nasal spray effectively relieves nasal congestion in adults and children with AR, while providing excellent safety and tolerability. 相似文献
48.
《Expert Review of Clinical Immunology》2013,9(6):503-505
Evaluation of: Laharie D, Bourreille A, Branche J et al.; Groupe d’Etudes Thérapeutiques des Affections Inflammatoires Digestives. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet 380(9857), 1909–1915 (2012).Severe active refractory ulcerative colitis is a potentially life-threatening disease. The introduction of intensive steroid treatment and early surgery has reduced mortality in recent years. Ciclosporin and infliximab are effective rescue therapies in steroid refractory colitis. A head-to-head study proposed by Laharie et al. failed to demonstrate the superiority of ciclosporin but confirmed the efficacy and safety of infliximab to control active disease and to maintain remission. 相似文献
49.
50.